Cytokinetics Incorporated

52.50-1.04-1.94%Vol 1.58M1Y Perf 67.89%
Aug 9th, 2022 16:00 DELAYED
BID47.09 ASK54.87
Open52.57 Previous Close53.54
Pre-Market- After-Market54.87
 - -  2.37 4.51%
Target Price
64.55 
Analyst Rating
Strong Buy 1.15
Potential %
22.95 
Finscreener Ranking
★+     44.22
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     43.37
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     40.61
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
91.26 
Earnings Rating
Sell
Market Cap4.94B 
Earnings Date
4th Aug 2022
Alpha0.02 Standard Deviation0.16
Beta1.18 

Today's Price Range

51.1153.87

52W Range

29.1054.74

5 Year PE Ratio Range

-8.8050.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
26.30%
1 Month
15.14%
3 Months
53.10%
6 Months
36.86%
1 Year
67.89%
3 Years
296.30%
5 Years
331.77%
10 Years
1 212.25%

TickerPriceChg.Chg.%
CYTK52.50-1.0400-1.94
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
-168.10
-347.20
-342.50
-405.90
-
RevenueValueIndustryS&P 500US Markets
62.19M
0.73
30.92
12.23
Earnings HistoryEstimateReportedSurprise %
Q02 2022-1.04-0.2377.88
Q01 2022-0.93-1.02-9.68
Q04 2021-0.89-0.3659.55
Q03 2021-0.75-0.95-26.67
Q02 2021-0.65-0.86-32.31
Q01 2021-0.59-0.66-11.86
Q04 2020-0.48-0.62-29.17
Q03 2020-0.59-0.0591.53
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.04-7.22Negative
9/2022 QR-1.11-13.27Negative
12/2022 FY-4.36-15.04Negative
12/2023 FY-4.17-18.80Negative
Next Report Date-
Estimated EPS Next Report-1.04
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume1.58M
Shares Outstanding94.14K
Shares Float59.21M
Trades Count22.59K
Dollar Volume83.37M
Avg. Volume1.52M
Avg. Weekly Volume1.96M
Avg. Monthly Volume1.30M
Avg. Quarterly Volume1.30M

Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 53.54 per share at the end of the most recent trading day (a 3.32% change compared to the prior day closing price) with a volume of 2.49M shares and market capitalization of 4.94B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.

The one-year performance of Cytokinetics Incorporated stock is 67.89%, while year-to-date (YTD) performance is 17.46%. CYTK stock has a five-year performance of 331.77%. Its 52-week range is between 29.1 and 54.74, which gives CYTK stock a 52-week price range ratio of 91.26%

Cytokinetics Incorporated currently has a PE ratio of -12.70, a price-to-book (PB) ratio of 29.84, a price-to-sale (PS) ratio of 53.08, a price to cashflow ratio of 409.20, a PEG ratio of 2.32, a ROA of -36.78%, a ROC of -61.60% and a ROE of -285.76%. The company’s profit margin is -%, its EBITDA margin is -342.50%, and its revenue ttm is $62.19 Million , which makes it $0.73 revenue per share.

Of the last four earnings reports from Cytokinetics Incorporated, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.04 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.15), with a target price of $64.55, which is +22.95% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cytokinetics Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 9.63, ATR14 : 3.06, CCI20 : 250.95, Chaikin Money Flow : 0.13, MACD : 1.64, Money Flow Index : 81.65, ROC : 35.54, RSI : 68.84, STOCH (14,3) : 92.71, STOCH RSI : 1.00, UO : 68.40, Williams %R : -7.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: B. Lynne Parshall (Option Excercise at a value of $451 052), B. Lynne Parshall (Sold 41 328 shares of value $1 609 047 ), Ching W. Jaw (Option Excercise at a value of $484 000), Ching W. Jaw (Sold 75 687 shares of value $2 865 185 ), David W. Cragg (Option Excercise at a value of $584 250), David W. Cragg (Sold 93 269 shares of value $3 532 061 ), Edward M. Kaye (Option Excercise at a value of $114 150), Edward M. Kaye (Sold 15 000 shares of value $675 000 ), Fady Ibraham Malik (Option Excercise at a value of $1 033 670), Fady Ibraham Malik (Sold 144 153 shares of value $5 680 287 ), John T. Henderson (Option Excercise at a value of $72 744), John T. Henderson (Sold 8 503 shares of value $340 120 ), Leonard Patrick Gage (Option Excercise at a value of $112 400), Leonard Patrick Gage (Sold 26 468 shares of value $1 094 023 ), Mark A. Schlossberg (Option Excercise at a value of $789 089), Mark A. Schlossberg (Sold 45 175 shares of value $1 569 694 ), Robert I. Blum (Option Excercise at a value of $1 243 878), Robert I. Blum (Sold 164 143 shares of value $6 273 276 ), Sandford Drexel Smith (Option Excercise at a value of $979 397), Sandford Drexel Smith (Sold 57 322 shares of value $2 491 674 ), Santo J. Costa (Option Excercise at a value of $106 800), Santo J. Costa (Sold 10 000 shares of value $373 477 ), Wendell D. Wierenga (Option Excercise at a value of $22 746), Wendell D. Wierenga (Sold 4 166 shares of value $184 854 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
9 (75.00 %)
9 (75.00 %)
Moderate Buy
2 (20.00 %)
3 (25.00 %)
3 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.15
Strong Buy
1.21
Strong Buy
1.21

Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

CEO: Robert I. Blum

Telephone: +1 650 624-3000

Address: 280 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 156

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

67%33%

Bearish Bullish

50%50%

TipRanks News for CYTK

Fri, 05 Aug 2022 04:46 GMT Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Cytokinetics (CYTK) and Sarepta Therapeutics (SRPT)

- TipRanks. All rights reserved.

Tue, 26 Jul 2022 15:45 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and IVERIC bio (ISEE)

- TipRanks. All rights reserved.

Fri, 08 Jul 2022 12:06 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Resmed (RMD) and BioSig Technologies (BSGM)

- TipRanks. All rights reserved.

Fri, 24 Jun 2022 12:57 GMT Mizuho Securities Believes Cytokinetics (CYTK) Still Has Room to Grow

- TipRanks. All rights reserved.

Mon, 13 Jun 2022 15:45 GMT Cytokinetics (CYTK) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Tue, 24 May 2022 12:50 GMT Cytokinetics (CYTK) Receives a Buy from Goldman Sachs

- TipRanks. All rights reserved.

Tue, 24 May 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Qiagen (QGEN) and United Therapeutics (UTHR)

- TipRanks. All rights reserved.

Thu, 05 May 2022 04:25 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: AxoGen (AXGN), Cytokinetics (CYTK) and Mirati Therapeutics (MRTX)

- TipRanks. All rights reserved.

Thu, 14 Apr 2022 09:45 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Masimo (MASI)

- TipRanks. All rights reserved.

Sun, 03 Apr 2022 23:45 GMT Cytokinetics (CYTK) Gets a Buy Rating from Mizuho Securities

- TipRanks. All rights reserved.

Fri, 04 Mar 2022 12:10 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Cooper Co (COO), Cytokinetics (CYTK) and Singular Genomics Systems (OMIC)

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 15:45 GMT Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Cytokinetics (CYTK) and Neoleukin Therapeutics (NLTX)

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 14:44 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Henry Schein (HSIC) and Applied Genetic Technologies (AGTC)

- TipRanks. All rights reserved.

Tue, 15 Feb 2022 14:30 GMT Cytokinetics (CYTK) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Fri, 04 Feb 2022 15:35 GMT Cytokinetics (CYTK) Gets a Buy Rating from Needham

- TipRanks. All rights reserved.

Fri, 04 Feb 2022 15:15 GMT Cytokinetics (CYTK) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Sun, 16 Jan 2022 09:06 GMT Analysts Offer Insights on Healthcare Companies: and Cytokinetics (CYTK)

- TipRanks. All rights reserved.

Mon, 10 Jan 2022 05:25 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Altimmune (ALT)

- TipRanks. All rights reserved.

News

Stocktwits